太阳集团tyc5997_平台(china)官方网站

衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)

Multiplex Assay Kit for Fibulin 3 (FBLN3) ,etc. by FLIA (Flow Luminescence Immunoassay)

EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5

(注:单次混测多因子不超过8个指标 )

  • 衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法) 产品包装(模拟)
  • 衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法) 产品包装(模拟)
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

特异性

本试剂盒用于检测衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。

回收率

分别于定值血清及血浆样本中加入一定量的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。

样本 回收率范围(%) 平均回收率(%)
serum(n=5) 97-105 101
EDTA plasma(n=5) 90-98 94
heparin plasma(n=5) 83-93 87

精密度

精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%

线性

在定值血清及血浆样本内加入适量的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)含量的测定值与理论值的比率。

样本 1:2 1:4 1:8 1:16
serum(n=5) 92-103% 78-97% 85-104% 87-101%
EDTA plasma(n=5) 86-93% 93-104% 80-91% 92-105%
heparin plasma(n=5) 91-99% 83-92% 80-96% 84-92%

稳定性

经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。

实验流程

1. 实验前标准品、试剂及样本准备;
2. 加样(标准品、样本、磁珠)标准品或样本100μL及磁珠10μL,
    37°C酶标板振荡器孵育90分钟;
3. 磁吸甩干,加检测溶液A100μL,37°C酶标板振荡器孵育60分钟;
4. 磁吸洗板3次;
5. 加检测溶液B100μL,37°C振动孵育30分钟;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋涡震荡2分钟后读数。

实验原理

将衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)抗体包被于磁珠,制成固相载体,向微孔中分别加入标准品或标本以及磁珠,其中的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)与连接于固相载体上的抗体结合,然后加入生物素化的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)抗体,将未结合的生物素化抗体洗净后,加入PE标记的亲和素,再次彻底洗涤后即可上机读数。MFI值和样品中的衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法)呈正相关。

赠品

相关产品

编号 适用物种:Homo sapiens (Human,人) 应用(仅供研究使用,不用于临床诊断!)
RPF422Hu02 衰老关键蛋白3(FBLN3)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPF422Hu01 衰老关键蛋白3(FBLN3)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAF422Hu01 衰老关键蛋白3(FBLN3)多克隆抗体 WB; IHC; ICC; IP.
PAF422Hu02 衰老关键蛋白3(FBLN3)多克隆抗体 WB; IHC; ICC; IP.
LAF422Hu71 衰老关键蛋白3(FBLN3)多克隆抗体(生物素标记) WB; IHC; ICC.
MAF422Hu23 衰老关键蛋白3(FBLN3)单克隆抗体 WB; IHC; ICC; IP.
MAF422Hu24 衰老关键蛋白3(FBLN3)单克隆抗体 WB; IHC; ICC; IP.
MAF422Hu22 衰老关键蛋白3(FBLN3)单克隆抗体 WB
MAF422Hu25 衰老关键蛋白3(FBLN3)单克隆抗体 WB
MAF422Hu21 衰老关键蛋白3(FBLN3)单克隆抗体 WB
SEF422Hu 衰老关键蛋白3(FBLN3)检测试剂盒(酶联免疫吸附试验法) Enzyme-linked immunosorbent assay for Antigen Detection.
SCF422Hu 衰老关键蛋白3(FBLN3)检测试剂盒(化学发光免疫分析法) Chemiluminescent immunoassay for Antigen Detection.
LMF422Hu 衰老关键蛋白3(FBLN3)等多因子检测试剂盒(流式荧光发光法) FLIA Kit for Antigen Detection.

参考文献

杂志 参考文献
1 Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma [PubMed: PMC3761217]
Anticancer Res. YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. [Pubmed: 24324091]
Oncology Reports Role of fibulin-3 in lung cancer: In vivo and in vitro analyses [Spandidos-publications: Source]
Current Pulmonology Reports Discovery of new biomarkers for malignant mesothelioma [Springer:Source]
United States Patent Application 20140378336 DIAGNOSIS OF CELL PROLIFERATIVE DISEASES [Freepatentsonline:Source]
Thorax. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma [Pubmed:Pmc4174124]
Egyptian Journal of Chest Diseases and Tuberculosis Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions [Pubmed:23050525]
Radiol Oncol Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma [PubMed: 26401134]
British Journal of Cancer Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis [PubMed: 26263483]
J Thorac Oncol. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. [Pubmed:26903362]
BMJ Open Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study [pubmed:27884852]
25 HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients [pubmed:26733616]
BMJ Journals Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational … [e013324.abstract]
Anticancer Res. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. [pubmed:28314308]
Dis Markers. A Novel Panel of Serum Biomarkers for MPM Diagnosis. [pubmed:28348450]
The Knee Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study [pubmed:29195846]
Disease markers Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population [pubmed:29200597]
Molecular Medicine Reports Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes [Pubmed:29749501]
Oncotarget The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion [Pubmed:30046386]
Advances in Clinical and Experimental Medicine Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with … [68362.pdf]
PLoS One Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals [Pubmed: 30946771]
留言咨询
Baidu
sogou